In a report released today, Carter Gould from Barclays maintained a Hold rating on Bristol Myers (BMY – Research Report). The company’s shares closed yesterday at $72.77.
According to TipRanks, Gould is a 3-star analyst with an average return of 1.4% and a 52.71% success rate. Gould covers the Healthcare sector, focusing on stocks such as Amgen, Biogen, and Eli Lilly & Co.
Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $82.00, implying a 12.68% upside from current levels. In a report released on January 31, UBS also maintained a Hold rating on the stock with a $77.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $80.80 and a one-year low of $61.06. Currently, Bristol Myers has an average volume of 8.99M.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Notable companies reporting before tomorrow’s open
- Prothena reports ‘positive’ topline Phase 1 study results for PRX005
- Bristol-Myers announces CHMP opinion recommending approval for Reblozyl
- Bristol-Myers’ Sotyktu recommended for approval in psoriasis by Europe’s CHMP